The estimated Net Worth of Denis R Burger is at least $148 Tisíc dollars as of 20 December 2021. Denis Burger owns over 10,000 units of Aptose Biosciences Inc stock worth over $11,687 and over the last 6 years he sold APTO stock worth over $0. In addition, he makes $136,630 as Lead Independent Director at Aptose Biosciences Inc.
Denis has made over 2 trades of the Aptose Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of APTO stock worth $14,500 on 20 December 2021.
The largest trade he's ever made was buying 10,000 units of Aptose Biosciences Inc stock on 20 December 2021 worth over $14,500. On average, Denis trades about 1,713 units every 3 days since 2019. As of 20 December 2021 he still owns at least 31,671 units of Aptose Biosciences Inc stock.
You can see the complete history of Denis Burger stock trades at the bottom of the page.
Dr. Denis R. Burger Ph.D. serves as Lead Independent Director of the Company. He co-founded Trinity Biotech, PLC, a diagnostic biotechnology company based in Dublin, Ireland, in 1992, served as Chairman from 1992 to 1995, and now serves as lead director on its Board of Directors. Dr. Burger served as the Chairman, Chief Executive Officer and a Director of AVI Biopharma Inc., an Oregonbased biotechnology company, from 1996 to 2007. Dr. Burger has also been the sole member of Paradigm Ventures LLC, a healthcare consulting and funding firm based in Portland, Oregon, since 1990. He was a cofounder and Chairman of Epitope Inc. from 1981 to 1990. Dr. Burger was Vice Chairman and Chief Scientific Officer of CytoDyn Inc. from 2016 to 2018. Dr. Burger has served as President of Yamhill Valley Vineyards since 1983. In addition, Dr. Burger previously held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health Sciences University in Portland. Dr. Burger received his M.Sc. and Ph.D. in Microbiology and Immunology from the University of Arizona.
As the Lead Independent Director of Aptose Biosciences Inc, the total compensation of Denis Burger at Aptose Biosciences Inc is $136,630. There are 6 executives at Aptose Biosciences Inc getting paid more, with William Rice having the highest compensation of $1,511,900.
Denis Burger is 75, he's been the Lead Independent Director of Aptose Biosciences Inc since 2011. There are no older and 12 younger executives at Aptose Biosciences Inc.
Denis's mailing address filed with the SEC is 251 Consumers Rd #1105, North York, ON M2J 1R3, Canada.
Over the last 6 years, insiders at Aptose Biosciences Inc have traded over $2,827,381 worth of Aptose Biosciences Inc stock and bought 538,629 units worth $767,189 . The most active insiders traders include Erich Platzer, Bernd R. Seizinger a William G. Rice. On average, Aptose Biosciences Inc executives and independent directors trade stock every 59 days with the average trade being worth of $14,277. The most recent stock trade was executed by Bernd R. Seizinger on 22 September 2023, trading 17,000 units of APTO stock currently worth $53,380.
aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
Aptose Biosciences Inc executives and other stock owners filed with the SEC include: